Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
Titel:
Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
Auteur:
Huang, Min A. Fasching, Peter Haiderali, Amin Xue, Weiguang Yang, Chelsey Pan, Wilbur Zhou, Zheng-Yi Hu, Peter Chaudhuri, Mitashri Le Bailly De Tilleghem, Celine Cappoen, Nicolas O’Shaughnessy, Joyce